Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Directed Evolution . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112063610B details TPL mutants achieving 146g/L L-DOPA. Offers superior catalytic efficiency for pharmaceutical manufacturing supply chains.
Discover advanced biocatalytic synthesis for ticagrelor intermediates using engineered ketoreductase. Achieve high substrate loading and cost reduction in pharmaceutical manufacturing.
Discover the breakthrough SmCR mutant technology for synthesizing optically pure gamma/delta-lactones. Achieve high conversion and purity with our reliable flavor intermediate supply chain solutions.
Patent CN109295026B reveals a high-efficiency enzymatic route for Zalcitabine. Discover cost-effective biocatalysis solutions for nucleoside analogues manufacturing.
Patent CN109402074B reveals high-activity monooxygenase mutants for chiral sulfoxide production. Discover cost reduction in pharmaceutical intermediate manufacturing and reliable supply chain solutions.
Patent CN108048438B reveals a novel halohydrin dehalogenase mutant for efficient Atorvastatin side chain synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN116004562A reveals a quadruple transaminase mutant boosting D-4,4'-biphenylalanine production efficiency by 30-fold, offering a scalable, high-purity solution for LCZ696 intermediates.
Patent CN110257351A reveals high-activity enzyme mutants for chiral alcohol synthesis offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN116515782A reveals a novel amine dehydrogenase mutant for high-purity chiral amine alcohol production, offering significant cost and safety advantages.
Patent CN117568294A reveals P450 mutant for S-halohydrins. Offers green synthesis and supply chain stability for pharma intermediates.
Patent CN118272331B reveals high-efficiency ene reductase mutant for (R)-citronellal. Delivers superior optical purity and scalable biocatalysis for global supply chains.
Patent CN119506235A reveals directed evolution for UDCA. Enhances supply chain stability and reduces manufacturing costs significantly.
Patent CN107099516B reveals a stable 7β-hydroxysteroid dehydrogenase mutant enabling high-concentration ursodeoxycholic acid synthesis with superior thermal stability and simplified downstream processing.
Patent CN112094856B discloses high-efficiency transaminase mutants for sitagliptin synthesis, achieving >99.95% e.e. and enabling significant cost reduction in API manufacturing.
Patent CN112175919B discloses engineered enzymes for efficient D-pantoic acid production, offering cost reduction and supply reliability for vitamin manufacturers.
Patent CN111100851B discloses high-efficiency TbSADH mutants for synthesizing chiral biaryl alcohols with >99% ee, offering a green alternative to metal catalysis.
Novel TbSADH mutants enable high-yield synthesis of chiral biaryl alcohols. Efficient biocatalysis for pharmaceutical intermediates with superior stereoselectivity.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
Patent CN113652408A reveals a novel carbonyl reductase mutant for efficient (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering superior yield and green manufacturing advantages.
Patent CN113444712B reveals novel L-aspartate-alpha-decarboxylase mutants boosting beta-alanine yields. Discover cost-effective biocatalysis solutions for pharma intermediates.